LATEST NEWS
November 22, 2017 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise November 21, 2017 | Company Announcements
Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox VaccineNovember 09, 2017 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV VaccineNovember 08, 2017 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2017 September 27, 2017 | Company Announcements
Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. GovernmentSeptember 21, 2017 | Company Announcements
Bavarian Nordic Provides Update on its Universal RSV VaccineSeptember 14, 2017 | Company Announcements
Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic’s Phase 3 Study of PROSTVAC in Metastatic Prostate CancerAugust 25, 2017 | Company Announcements
Bavarian Nordic Announces First Half 2017 ResultsAugust 22, 2017 | Company Announcements
Bavarian Nordic A/S Announces Major Shareholder Notification from Johnson & Johnson Innovation – JJDC, Inc.August 21, 2017 | Company Announcements
Bavarian Nordic Announces Closing of Transaction with Janssen Pharmaceuticals, Inc. and Issue of Shares to Johnson & Johnson Innovation – JJDC, Inc.